In the last trading session, 2.67 million SpringWorks Therapeutics Inc (NASDAQ:SWTX) shares changed hands as the company’s beta touched 0.80. With the company’s per share price at $32.50 changed hands at -$4.51 or -12.19% during last session, the market valuation stood at $2.42B. SWTX’s last price was a discount, traded about -65.91% off its 52-week high of $53.92. The share price had its 52-week low at $28.21, which suggests the last value was 13.2% up since then. When we look at SpringWorks Therapeutics Inc’s average trading volume, we note the 10-day average is 1.82 million shares, with the 3-month average coming to 1.25 million.
Analysts gave the SpringWorks Therapeutics Inc (SWTX) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.12. If we narrow down to specifics, the data shows that 0 out of 3 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended SWTX as a Hold, 3 felt it is a Buy and 0 rated the stock as Underweight. SpringWorks Therapeutics Inc’s EPS for the current quarter is expected to be -0.7.
SpringWorks Therapeutics Inc (NASDAQ:SWTX) trade information
Instantly SWTX was in red as seen at the end of in last trading. With action -16.37%, the performance over the past five days has been red. The company’s shares are showing year-to-date downside of -10.05%, with the 5-day performance at -16.37% in the red. However, in the 30-day time frame, SpringWorks Therapeutics Inc (NASDAQ:SWTX) is -18.24% down. Looking at the short shares, we see there were 12.27 million shares sold at short interest cover period of 12.78 days.
The consensus price target for the stock as assigned by Wall Street analysts is 77, meaning bulls need an upside of 57.79% from its current market value. According to analyst projections, SWTX’s forecast low is 76 with 78 as the target high. To hit the forecast high, the stock’s price needs a -140.0% plunge from its current level, while the stock would need to soar -133.85% for it to hit the projected low.
SpringWorks Therapeutics Inc (SWTX) estimates and forecasts
Data shows that the SpringWorks Therapeutics Inc share is performing relatively much better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot -22.32% over the past 6 months, a 39.42% in annual growth rate that is considerably higher than the industry average of 16.70%. Year-over-year growth is forecast to reach 3,330.97% up from the last financial year.
Consensus estimates given by 5 financial analysts project the company’s revenue in the current quarter to hit an average of 55.83M. 4 analysts are of the opinion that SpringWorks Therapeutics Inc’s revenue for the current quarter will be 67M. The company’s revenue for the corresponding quarters a year ago was 5.45M and 21.01M respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at 925.05%. The estimates for the next quarter sales put growth at 218.97%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -65.72%. The 2025 estimates are for SpringWorks Therapeutics Inc earnings to increase by 39.49%.
SWTX Dividends
SpringWorks Therapeutics Inc is expected to release its next quarterly earnings report in February.
SpringWorks Therapeutics Inc (NASDAQ:SWTX)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 1.92% of SpringWorks Therapeutics Inc shares while 115.94% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 118.20%. There are 115.94% institutions holding the SpringWorks Therapeutics Inc stock share, with FMR LLC the top institutional holder. As of 2024-06-30, the company held 15.0638% of the shares, roughly 11.11 million SWTX shares worth $418.6 million.
VANGUARD GROUP INC holds the second largest percentage of outstanding shares, with 8.8715% or 6.54 million shares worth $246.53 million as of 2024-06-30.
Among Mutual Funds, the top two as of Nov 30, 2024 were Fidelity Growth Company Fund and Vanguard Total Stock Market Index Fund . With 3.61 shares estimated at $117.19 million under it, the former controlled 4.85% of total outstanding shares. On the other hand, Vanguard Total Stock Market Index Fund held about 2.82% of the shares, roughly 2.1 shares worth around $68.18 million.
